News

Article

Pharmaceutical Technology

Pharmaceutical Technology, APIs, Excipients, and Manufacturing, October 2021
Volume
Pages: 58–67

Pharmaceutical Knowledge Management: Experiences in Drug Development and Manufacturing

Author(s):

Marco Adami,Alessandro Regola

Knowledge management has gained increasing importance in the pharmaceutical industry over the past 10–15 years

Knowledge Management

WRIGHTSTUDIO - STOCK.ADOBE.COM

Knowledge management has always been a key factor for the successful development and manufacture of pharmaceutical products. Understanding the chemical and physical processes underlying material interactions in dosage forms formulation, production processes, and product storage along its shelf-life is fundamental in assuring quality, efficacy, and safety of medicinal products. Knowledge has always directed the design of dosage forms (e.g., in terms of selection of excipients and primary packaging materials) and the development of production processes (e.g., in terms of process technology applied and process controls implemented).

Knowledge is normally assumed to be a combination of education and experience. Advanced education on chemistry, physics, microbiology, biology, analytics, materials properties, process technology, pharmacokinetics, pharmacology, toxicology, and physiology must be available in the pharmaceutical industry. Nowadays this ‘traditional’ form of education has to be integrated with a decent knowledge of information technology, data management, and processing. In addition, highly innovative and specialized areas, like biotech or advanced therapy, require specific knowledge of biochemistry, genomics, and cell engineering.

Read this article in Pharmaceutical Technology’s October 2021 APIs, Excipients, and Manufacturing eBook.

APIs, Excipients, and Manufacturing eBook

Read the article:

Pharmaceutical Knowledge Management: Experiences in Drug Development and Manufacturing

Read the eBook:

Pharmaceutical Technology’s APIs, Excipients, and Manufacturing eBook

About the Authors

Alessandro Regola,* a.regola@libero.it, is the AFI vice president in Milan and coordinator of the AFI Quality Section, and Marco Adami is an AFI member in Milan and coordinator of the Validation Group within the AFI Quality Section. They both serve as pharmaceutical consultants in quality systems and research and development, respectively.
*To whom all correspondence should be sent.

Article Details

Pharmaceutical Technology
eBook: APIs, Excipients, and Manufacturing
October 2021
Pages: 58–67

Citation

When referring to this article, please cite it as M. Adami and A. Regola, “Pharmaceutical Knowledge Management: Experiences in Drug Development and Manufacturing,” Pharmaceutical Technology’s APIs, Excipients, and Manufacturing eBook (October 2021).

Articles in this issue
Knowledge Management
Pharmaceutical Knowledge Management: Experiences in Drug Development and Manufacturing
Shining a Light on Photochemistry in Flow
Shining a Light on Photochemistry in Flow
Predicting Tablet Potency in Continuous Manufacturing
Predicting Tablet Potency in Continuous Manufacturing
Powder Testing
Building Robust Specifications Using Powder Testing
Global Regulatory Approach to API Manufacturing
Global Regulatory Approach to API Manufacturing
Seeking Economies of Scale for Biocatalysis
Seeking Economies of Scale for Biocatalysis
API Development and Manufacturing: Advantages of Working with Small Molecules
API Development and Manufacturing: Advantages of Working with Small Molecules
Rethinking, Recalibrating, and Retooling

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com
August 4th 2025

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Patrick Lavery
The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 4th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
White House | Image Credit: © Zack Frank - stock.adobe.com
August 4th 2025

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Patrick Lavery
If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 4th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
Kratom or Mitragyna speciosa on natural background. | Image Credit: © wasanajai - stock.adobe.com
August 4th 2025

FDA Seeks Scheduling Action to Control Harmful Kratom Plant Byproduct

Patrick Lavery
7-OH and the leaf of the kratom plant are not analogous, but as the former is a derivative of the latter, it has opioid-like qualities that make its susceptibility to abuse concerning.
Silver Spring, MD, USA - June 25, 2022: Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services. | Image Credit: © Tada Images - stock.adobe.com
August 4th 2025

3 Reasons FDA Says Quality Investments Are Essential for Drug Manufacturers and Patients

Patrick Lavery
FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and help prevent drug shortages.